<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559091</url>
  </required_header>
  <id_info>
    <org_study_id>CR0620KB</org_study_id>
    <secondary_id>REC:06-112</secondary_id>
    <nct_id>NCT00559091</nct_id>
  </id_info>
  <brief_title>A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia</brief_title>
  <acronym>Borden-001</acronym>
  <official_title>A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ribavirin (a drug commonly used to treat
      hepatitis C) also has activity in the treatment of patients with refractory or relapsed acute
      myeloid leukemia (AML) of the M4 and M5 subtype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eukaryotic translation initiation factor eIF4E is dysregulated in many human
      malignancies, including a subset of myeloid leukemia (M4/M5 AML and blast crisis CML). eIF4E
      overexpression leads to oncogenic transformation. Ribavirin impedes eIF4E mediated
      transformation in vitro, in primary human specimens and in animal models.

      While ribavirin has been used extensively for the treatment of viral hepatitis C and its
      safety profile has been well defined, it has never been used in patients with AML. This study
      will establish the efficacy and safety of ribavirin in M4/M5 AML patients. In addition, this
      study will also include correlative studies to determine the effect of ribavirin on eIF4E
      activity and eIF4E related pathways in M4/M5 AML patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Overall response rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure: Safety and tolerability, correlative studies</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Acute Myelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Ribasphere (Three Rivers Pharmaceuticals)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of acute myeloid leukemia (AML), either M4 or M5 subtype de novo or
             resulting from a transformation from MDS or a myeloproliferative disorder.

          -  Patients with AML who (a) have failed primary therapy -defined as failing two
             induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive
             induction chemotherapy will be eligible. OR

          -  Patients with AML blast crisis from CML if they are not suitable candidates for
             intensive induction chemotherapy or have failed imatinib mesylate OR

          -  Patients with secondary AML after MDS if they are not suitable candidates for
             intensive induction chemotherapy.

          -  ECOG 0,1,2, or 3

          -  Life expectancy &gt; 12 weeks.

          -  Adequate renal and hepatic function

        Exclusion Criteria:

          -  Uncontrolled central nervous system involvement by AML

          -  Active cardiovascular disease as defined by NYHA class III-IV categorization.

          -  Intercurrent illness or medical condition precluding safe administration of ribavirin.

          -  Received any previous therapy within 28 days prior to study entry.Hydrea is permitted
             but must be stopped 7 days prior to starting study drug.

          -  Known infection with HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarit Assouline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathy Borden, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ribatrial.com</url>
    <description>Click here for more information about the study.</description>
  </link>
  <reference>
    <citation>Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003 Dec;23(24):8992-9002.</citation>
    <PMID>14645512</PMID>
  </reference>
  <reference>
    <citation>De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol. 1999 Jan;31(1):59-72. Review.</citation>
    <PMID>10216944</PMID>
  </reference>
  <reference>
    <citation>Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18105-10. Epub 2004 Dec 15.</citation>
    <PMID>15601771</PMID>
  </reference>
  <reference>
    <citation>Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr, Borden KL. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009 Jul 9;114(2):257-60. doi: 10.1182/blood-2009-02-205153. Epub 2009 May 11.</citation>
    <PMID>19433856</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>May 6, 2011</last_update_submitted>
  <last_update_submitted_qc>May 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Sarit Assouline / Associate Director, Clinical Research Unit</name_title>
    <organization>Jewish General Hospital, McGill University</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute myelocytic leukemia</keyword>
  <keyword>leukemia</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>M4</keyword>
  <keyword>M5</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

